APA

Santegoets S. J., Stam A. G., Lougheed S. M., Gall H., Jooss K., Sacks N., Hege K., Lowy I., Scheper R. J., Gerritsen W. R., van den Eertwegh A. J. & de Gruijl T. D. (20150721). Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. : Journal for immunotherapy of cancer.

Chicago

Santegoets Saskia Jam, Stam Anita Gm, Lougheed Sinéad M, Gall Helen, Jooss Karin, Sacks Natalie, Hege Kristen, Lowy Israel, Scheper Rik J, Gerritsen Winald R, van den Eertwegh Alfons Jm and de Gruijl Tanja D. 20150721. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. : Journal for immunotherapy of cancer.

Harvard

Santegoets S. J., Stam A. G., Lougheed S. M., Gall H., Jooss K., Sacks N., Hege K., Lowy I., Scheper R. J., Gerritsen W. R., van den Eertwegh A. J. and de Gruijl T. D. (20150721). Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. : Journal for immunotherapy of cancer.

MLA

Santegoets Saskia Jam, Stam Anita Gm, Lougheed Sinéad M, Gall Helen, Jooss Karin, Sacks Natalie, Hege Kristen, Lowy Israel, Scheper Rik J, Gerritsen Winald R, van den Eertwegh Alfons Jm and de Gruijl Tanja D. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. : Journal for immunotherapy of cancer. 20150721.